Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Explore this paper's citation graph

Summary

Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.

Type
article
Published
1998-08-19
Cited by
6,411
References
59

Keywords

Medicine, Medroxyprogesterone acetate, Myocardial infarction, Hazard ratio, Internal medicine

References

Cited by

Related papers